MedTrace Logo

Outcome of Treatment of Uveitis With Biologic Drugs in Resistant Cases Vogt-koyanagi-Harada Disease

NCT05349747 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2022-04-27

No results posted yet for this study

Summary

* Reviewing the characteristics of patients with uveitis caused by Vogt-Koyanagi-Harada Syndrome treated at Assiut University Hospital at the Department of Ophthalmology and Department of Rheumatology, Physical Medicine, and Rehabilitation including the ocular features in terms of uveitis location, type and complications and systemic features of those subjects who showed an inadequate response to conventional immunomodulatory drugs.
* Assess the results of treatment with biologic drugs, including rates of failure and adverse events. This will help uveitis specialists to reach a conclusion about the best treatment protocols for Uveitis in Vogt-Koyanagi-Harada Syndrome in our population in terms of safety, efficacy, and cost-effectiveness.

Conditions

  • Uveitis

Interventions

BIOLOGICAL

Biologic drugs

Assess the results of treatment with biologic drugs

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Salma Safwat, Master · Assiut University

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-30
Primary Completion
2024-04-30
Completion
2024-08-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05349747 on ClinicalTrials.gov